Sign Up to like & get
recommendations!
0
Published in 2021 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-021-02043-2
Abstract: Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, its effectiveness and safety in patients with poor performance status…
read more here.
Keywords:
egfr;
tki;
positive advanced;
progression ... See more keywords